drugset

drugset / Trial / NCT03617679

Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer

NCT03617679 ↗

Phase 2 Completed 79 enrolled University of Colorado, Denver Clovis Oncology, Inc. · collab National Cancer Institute (NCI) · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

This study seeks to determine the effectiveness of Rucaparib as maintenance therapy for metastatic and recurrent endometrial cancer, after 1-2 prior lines of therapy.

Timeline

Start: 2019-03-06
Primary completion: 2023-10-31
Completion: 2026-02-27

Publications

Corr BR, Haggerty A, Gysler SM, Taylor S, Behbakht K, Alldredge J, Lefkowits C, Brubaker LW, Bouts C, Babayan LM, Martin LP, Costello J, Bitler BG, Hu J, Guntupalli SR. A phase II, randomized, double-blind study of the use of rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer. Gynecol Oncol. 2025 Sep;200:58-67. doi: 10.1016/j.ygyno.2025.07.008. Epub 2025 Jul 22.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Rucaparib	Small molecule	600 mg	Oral

Indications